Lion's Mane

Clinical Summary

Lion's Mane (Hericium erinaceus) is a medicinal and culinary mushroom producing two classes of neuroactive compounds: erinacines (from mycelia, cross BBB, stimulate NGF synthesis) and hericenones (from fruiting bodies, stimulate NGF peripherally). Beta-glucan polysaccharides provide immunomodulatory and gut health effects.

Who benefits most: Adults 50+ with mild cognitive impairment have the strongest evidence base (multiple RCTs). Healthy younger adults show modest acute and chronic cognitive/mood improvements in recent trials. The compound has an exceptionally clean safety profile and wide therapeutic window.

What matters clinically: The neurotrophic mechanism is validated — erinacines stimulate NGF via JNK pathway in astrocytes, and hericerin derivatives activate a pan-neurotrophic ERK1/2 pathway enhancing spatial memory (PMID: 36660878). Two independent RCTs confirm cognitive improvement in MCI (Mori 2009, Saitsu 2019). A pilot RCT shows promise for early AD prevention (Li 2020). Three studies show mood/stress benefits across different populations.

What doesn't yet hold up: Cancer claims are entirely preclinical (in vitro only). Metabolic, GI, and neuropathy claims rest on animal data. The popular "myelin regeneration" narrative has zero human evidence. Community reports of severe neuropsychiatric effects (r/LionsManeRecovery) are not reproduced in any clinical trial.

Key update (2026): 172 new publications (2024-2026), 2 newly completed RCTs on cognitive function in middle-aged adults (NCT07405632, NCT07405957), formal toxicology assessment published (PMID: 41230556), new domains emerging (hearing, retinal, osteoarthritis, male reproductive). FAERS shows zero suspect-drug reports — all 28 reports list Lion's Mane as concomitant only.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal-to-human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal-to-human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend:

Prescribing

Dosing Table

Formulation Table

Condition-Specific Protocols

Mild Cognitive Impairment Protocol

Evidence: 4/5 | PMIDs: 18844328, 31413233

Phase 1: Initiation (Weeks 1-2)

• Fruiting body extract 1000 mg/day with breakfast (fat-containing)
• Baseline cognitive testing: MMSE or MoCA
• Goal: Assess GI tolerance

Phase 2: Therapeutic (Weeks 3-16)

• Escalate to 3000 mg/day divided (1000 mg 3x daily with meals)
• MMSE/MoCA at week 8 and week 16
• Expected: Statistically significant improvement in cognitive scores by week 8

Phase 3: Maintenance (Week 16+)

• Continue 3000 mg/day (benefits reverse within 4 weeks of cessation per Mori 2009)
• Cognitive testing every 3-6 months
• Reassess annually whether to continue

Stop/Reassess: If no improvement by week 16; if GI intolerance persists despite dose reduction

Early Alzheimer's Prevention Protocol

Evidence: 3/5 | PMID: 32581767

Phase 1-2: EAHE 1050 mg/day (3x 350 mg capsules, 5 mg/g erinacine A) for 49 weeks Monitoring: MMSE, IADL assessments every 12 weeks Expected: MMSE stabilization vs expected decline; increased BDNF (blood biomarker) Stop/Reassess: This is a single unreplicated pilot (N=49). Manage expectations. Continue only if cognitive stability maintained.

Depression & Anxiety Protocol

Evidence: 3/5 | PMIDs: 20834180, 31118969, 38004235

Protocol: 2000 mg/day fruiting body extract divided (1000 mg morning + 1000 mg evening) for 4-8 weeks Monitoring: BDI-II, STAI, or PHQ-9 at baseline and week 4/8 Expected: Significant reduction in depression/anxiety scores by week 4; improved sleep quality Note: Best evidence is in menopausal women (Nagano 2010) and overweight individuals (Vigna 2019). Docherty 2023 extends to healthy young adults but with smaller effects.

Safety

Interactions Table

Contraindications

• Absolute: Known allergy to mushrooms or Hericium erinaceus
• Relative: Upcoming surgery within 2 weeks (theoretical bleeding; precautionary); severe immunosuppression (theoretical immune stimulation); pregnancy/lactation (no safety data)

Adverse Effects

Common (1-5%):

• GI discomfort: nausea, stomach pain, diarrhea — Management: take with food, reduce dose, divide doses
• Skin rash/itching (allergic) — Management: discontinue; antihistamines

Uncommon (0.1-1%):

• Headache (mechanism unclear)
• Fatigue/drowsiness (rare)
• Allergic respiratory symptoms (rhinitis, dyspnea) in mushroom-sensitive individuals

Rare (<0.1%):

• Anaphylaxis (extremely rare; case reports in mushroom-allergic individuals)
• Liver enzyme elevation: one case report of Grade 3 cytolysis in metastatic CRC patient consuming multi-mushroom blend (PMID: 39223928). Confounded by cancer, chemotherapy, and polysupplement use. Causality uncertain. Pharma skepticism note: single case in severely ill patient with multiple confounders — this is a 1/5 safety signal, not a class effect.

NOT confirmed in clinical trials but reported in online communities (see Community section):

• Libido/sexual dysfunction — based on misattributed species data (H. ramosum, not H. erinaceus); no clinical evidence
• Depersonalization/derealization — reported in r/LionsManeRecovery; not reproduced in any RCT; likely confounded by product quality, co-supplementation, and selection bias
• Anxiety worsening — paradoxical; contradicts clinical trial data showing anxiolytic effects

FAERS Signal Table

Reading FAERS data: Total 28 reports; zero list Lion's Mane as the suspect drug. All reports list pharmaceutical agents (rituximab, palbociclib, dupilumab, nivolumab, etc.) as suspect. Per FAERS supplement noise principle: these counts are entirely noise from patients on serious medications who also happen to take Lion's Mane. No actionable safety signal exists in FAERS for this compound.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Synergies & Stacking

No confirmed antagonistic interactions.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No other pharmacogenomic modifiers have been studied for this compound. Zero results for "Hericium erinaceus pharmacogenomics" in PubMed.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Mixed-to-Positive across ~2000-5000+ reports (Reddit, Longecity, WebMD, YouTube, forums). A vocal negative minority exists concentrated in r/LionsManeRecovery (~1000 members).

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No. Lion's Mane is not a primary MLM product. Clean on this dimension.
• Influencer concentration: Moderate concern. Andrew Huberman and Bryan Johnson have amplified interest. TikTok features heavily promotional content with unclear sponsorship. Not single-influencer-driven but influencer-accelerated.
• Astroturfing signals: Some Amazon review manipulation detected (Fakespot). No systematic astroturfing campaign identified. The broader mushroom supplement space has quality concerns.
• Commercial bias: Paul Stamets (Host Defense) is both a prominent researcher and supplement company owner — significant conflict of interest. The fruiting body vs mycelium debate has commercial undertones on both sides (Host Defense sells mycelium-on-grain; Real Mushrooms and Nootropics Depot sell fruiting body extracts).
• Product quality — the hidden variable: Most cheap products are "mycelium-on-grain" containing 60-70% grain starch with near-zero verified erinacines. This likely explains a large portion of the "works/doesn't work" divide. ConsumerLab found misleading labeling. No standardized erinacine A testing existed until ~2025 (Erinamax).
• Species confusion: The DHT/libido concern traces to a study on Hericium ramosum, NOT H. erinaceus. These are different species. Claims propagated without correction.
• FDA warning letters: Issued to manufacturers for unsubstantiated drug claims and GMP violations.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: cognitive clarity improvements (multiple RCTs confirm), mood benefits (3 human studies support), GI side effects (confirmed in trials), and the 4-8 week onset window (matches trial timelines). Community experience diverges on: severe neuropsychiatric effects (depersonalization, anhedonia — zero signal in any RCT), libido reduction (species misattribution), and "life-changing" magnitude of effects (trials show modest, statistically significant improvements, not transformative ones). The most likely explanations for divergence are: product quality variation, placebo/nocebo effects, self-selection bias (r/LionsManeRecovery), and confounding from co-supplementation (especially with Reishi, which does have anti-androgenic properties).

Deep Dive: Mechanisms & Research

Primary Neurotrophic Mechanisms (Clinically Translated)

NGF Synthesis via JNK Pathway: Erinacine A stimulates NGF production in astrocytes through c-Jun N-terminal kinase signaling. Confirmed in human astrocytoma cells (PMID: 18758067). Clinical translation: the MCI and AD trials demonstrate cognitive improvement consistent with enhanced NGF activity.

Pan-Neurotrophic ERK1/2 Pathway: Hericerin derivatives activate NGF, BDNF, and NT-3 receptors converging to ERK1/2 signaling, enhancing neurite outgrowth and spatial memory (PMID: 36660878). This is the most comprehensive mechanistic finding — a single compound class activating multiple neurotrophic pathways simultaneously.

BDNF Enhancement: Human studies confirm increased pro-BDNF and mature BDNF levels (PMID: 31118969, Chan 2022). BDNF increase correlated with mood improvement, sleep quality, and hearing improvement.

Neurotrophic-Epigenetic Axis (New 2026): Proposed mechanism via non-coding RNA networks linking Lion's Mane neurotrophic activity to epigenetic regulation (PMID: 41683696). Hypothesis-stage but could explain long-term neuroprotective effects.

Secondary Mechanisms (Preclinical)

• Myelin regeneration: Promotes oligodendrocyte maturation and MBP production (PMID: 33753806). No human translation.
• Anti-amyloid: Reduces amyloid-beta plaque formation in animal models. Partially supported by Li 2020 AD trial (biomarker data).
• Anti-inflammatory: Inhibits NF-kB signaling (PMID: 41977330), JAK1/STAT3 pathway (PMID: 41168894). Suppresses TNF-alpha, IL-6, IL-1beta.
• Gut-brain axis: Beta-glucans serve as prebiotics, increasing SCFA-producing bacteria. Microbiome changes correlated with cognitive improvement in Li 2024 pilot.
• Anti-cancer: Apoptosis via caspase pathways, PI3K/AKT and RAS/MAPK inhibition (PMID: 39183463), erinacine S derivative overcomes chemoresistance via histone acetylation (PMID: 41209562). All in vitro. Zero in vivo tumor models.
• Nrf2 activation: Cerebral protection in mild TBI (PMID: 38539904) and SCA3 (PMID: 39765823) via Nrf2-dependent antioxidant pathways. Animal models.
• PPAR signaling: Novel metabolic pathway engagement identified (PMID: 41915570). Could explain anti-diabetic and hypolipidemic animal data.
• AhR activation in neurons: Novel pathway identified in HT-22 neuronal cells (PMID: 40810764).

Blood-Brain Barrier Penetration

• Erinacine A: Crosses BBB effectively (confirmed in animal studies with radiolabeled compounds; PMID: 34361662 validated LC-MS/MS method)
• Hericenones: Limited BBB penetration; primarily stimulate peripheral NGF synthesis
• Implication: For cognitive/neuro goals, erinacine-containing formulations (EAHE) are mechanistically superior. Fruiting body extracts work via peripheral NGF stimulation and hericenone activity.

New Compound Discoveries (2024-2026)

• Erinacerin W: Immunomodulatory + neuroprotective (PMID: 38398564, Taiwan)
• Hericium VN: Novel compound with cytotoxicity against brain astrocytoma (PMID: 38572975, Vietnam)
• Novel terpenoids: New neuroprotective terpenoids from fruiting bodies with structural elucidation (PMID: 40724855)
• Hericenone biosynthetic pathway: Prenyltransferases discovered (PMID: 40759078), enabling potential synthetic production

Emerging Domains (2024-2026)

• Retinal health: HE + Cordyceps cicadae promote neurite outgrowth of retinal ganglion cells (PMID: 41650116, Taiwan)
• Osteoarthritis: Combined EAHE + undenatured type II collagen reduces OA progression (PMID: 41799751, Taiwan)
• Male reproductive health: Mycelium improves reproductive dysfunction from polystyrene microplastics (PMID: 40565199, Taiwan)
• Pain/analgesia: Hericenone C attenuates nociceptive behavior via CD11c+/NF-kB suppression (PMID: 38759303, Japan)
• Radiation protection: Anti-radiation metabolomics of polysaccharides (PMID: 40350852, China)
• Spinocerebellar ataxia (SCA3): Erinacine A lessens cellular damage via Nrf2 (PMID: 39765823, Taiwan)
• Schizophrenia (adjunctive): Theoretical rationale for add-on to antipsychotics (PMID: 39935672)
• Post-COVID cognitive dysfunction: Proposed neuroprotective support (no studies yet)

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Regulatory Status

• FDA: Not approved as drug. Marketed as dietary supplement. GRAS-equivalent (no formal GRAS notification but long history of safe use). FDA has issued warning letters to manufacturers for drug claims.
• EMA: Not approved. No marketing authorization.
• Japan: Classified as food/functional food ("Yamabushitake"). Traditional culinary mushroom.
• Taiwan: EAHE products marketed as functional foods since 2015 (Grape King Bio). No reported adverse events.
• Regulatory context: Lion's Mane is a non-patentable natural product with centuries of culinary use. No pharmaceutical company has incentive to pursue NDA (cost ~$1B, no patent protection). "Not FDA-approved" reflects commercial reality, not a safety or efficacy failure.

Ataraxia Verdict (as of 2026-04-16)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature: "Medicinal mushroom" framing implies natural=effective. Lion's Mane IS active, but the "ancient wisdom" narrative inflates expectations beyond evidence.
• Hasty generalization: Animal-to-human extrapolation is rampant — myelin regeneration, cancer, diabetes, GI healing all claimed based on animal/in vitro data. None have human RCTs.
• Appeal to authority: Paul Stamets is cited as both scientist and product developer. His dual role as researcher and Host Defense CEO creates unacknowledged conflict of interest.
• Cherry-picking: Positive trials are small (N=30-50). Null or negative findings may exist unpublished (publication bias). The original file rated Li 2020 as 5/5 — a single pilot RCT with N=49 is not 5/5 by any standard.
• Argument from tradition: "Centuries of use in Chinese medicine" is used to bolster GI claims with zero human RCT data. Traditional use establishes safety, not efficacy for specific indications.

Evidence Gaps

• No dose-response studies in humans (wide range 1050-3000 mg/day used; optimal dose unknown)
• No head-to-head RCT comparing fruiting body vs mycelium vs dual extract
• No human pharmacokinetic studies (all bioavailability numbers are estimates)
• No studies >49 weeks (long-term safety unknown beyond ~1 year)
• No studies in children except one pilot in intellectual disability (PMID: 41599861)
• No pregnancy/lactation safety data
• Zero pharmacogenomic studies
• No peripheral neuropathy RCTs (strongest unmet potential)
• No human IBD RCTs (3-star traditional use + animal data awaiting human translation)
• No prevention trials in cognitively normal adults (the main consumer demographic)

Bias Flags (Mode 4: First Principles)

• What survives scrutiny: MCI improvement (2 RCTs, replicated). Safety profile (multiple tox studies, 14+ human trials, zero serious AEs attributed). NGF stimulation mechanism (validated in vitro, consistent with cognitive trial results).
• What doesn't survive: Five-star evidence claims for any indication. Animal-to-human leaps for cancer, myelin, diabetes. Precise bioavailability percentages (fabricated precision).
• Cui bono: The mushroom supplement industry is multi-billion dollar. Lion's Mane is a premium product ($30-70/month). Paul Stamets/Host Defense, Real Mushrooms, Nootropics Depot, and dozens of others have direct commercial interest. Taiwan's Grape King Bio holds EAHE patents and funds the Li 2020 trial. Industry-funded ≠ wrong, but independence should be weighted.
• Study population bias: Key RCTs are predominantly East Asian elderly. Generalizability to Western younger adults is assumed but not proven. The recent Docherty 2023 (UK, young adults) begins to address this gap.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Smart mushroom" / "brain mushroom" branding targets biohacker anxiety about cognitive decline. "Clinical-strength" claims appear on products with no relation to clinical trial formulations. "Mycelium on grain" controversy has marketing on both sides (Host Defense defends grain-based; competitors attack it).
• Influencer economics: Andrew Huberman, Bryan Johnson, and multiple biohacker YouTubers promote Lion's Mane. Some receive affiliate revenue or sponsorship. TikTok content is heavily promotional with unclear disclosure.
• Counter-narrative manipulation: The pharmaceutical industry has minimal incentive to attack Lion's Mane (it doesn't threaten donepezil/memantine revenue). Counter-narratives come mainly from competing supplement companies.
• Cui bono summary: Those who win if you take it: supplement companies, mushroom growers, biohacker content creators, functional food industry. Those who win if you don't: competing nootropic companies, pharmaceutical AD drug makers (minimal motivation). The incentive landscape tilts toward promotion rather than suppression.
• Red team highlight (most concerning angle): The 4-8 week onset timeline matches the natural resolution of many cognitive complaints (stress, sleep deprivation, seasonal mood). Without active placebo control, it's impossible to distinguish genuine neurotrophic effects from regression to the mean in healthy adults. The MCI trials controlled for this, but the "general wellness" market does not.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 7/10 — strong evidence for MCI, some evidence for mood in specific populations, clean safety profile and reasonable cost; high utility for adults 50+ with cognitive concerns, narrower breadth for metabolic/cardiovascular/musculoskeletal domains.
• Opportunity cost: $20-70/month; 1-3 pills/day; minimal attention cost; very low risk. Opportunity cost is low — adding Lion's Mane displaces very little.
• Verdict: CONDITIONAL
  • For MCI/early cognitive decline in adults 50+: ADD (4/5 evidence, safe, reasonable cost)
  • For mood support in specific populations (menopausal, overweight): ADD (3/5, safe, low cost)
  • For general cognitive wellness in healthy adults: WATCH LIST (3/5, promising but modest effects in healthy populations)
  • For all other indications (GI, metabolic, cancer, neuropathy): SKIP until human RCTs emerge

Bottom Line

Lion's Mane is one of the better-supported nootropic supplements — it has genuine neurotrophic activity, a clean safety profile, and moderate clinical evidence for cognitive improvement in MCI. It is not, however, the "brain miracle" that TikTok suggests. Effects are modest, most claims beyond cognition and mood are preclinical, and product quality varies enormously. The compound deserves its place in a cognitive support stack for at-risk populations but should not be expected to transform cognition in healthy young adults. The 2024-2026 research wave (172 new publications) is expanding the evidence base rapidly, with 4 recruiting trials that may upgrade several indications within 1-2 years.

Practical Notes

Brands & Product Selection

High-quality erinacine-rich mycelium:

• Erinamax (~2025, first verified erinacine A content)
• Host Defense (Paul Stamets; note: mycelium-on-grain, commercial bias)

High-quality fruiting body extracts:

• Real Mushrooms (>25% beta-glucans, COA available)
• Nootropics Depot (8:1 extraction, third-party tested)
• Oriveda (dual extraction, European quality standards)

Quality markers: COA (Certificate of Analysis) available; third-party heavy metal testing; beta-glucan >20%; alpha-glucan <5% (high alpha-glucan = grain filler); clear extraction method stated; GMP certification.

Red flags: "Mycelium on grain" without erinacine quantification; no COA; no beta-glucan claim; proprietary blends; extremely low prices; "cure" claims for AD or cancer.

Storage & Handling

• Temperature: 15-25C (room temperature)
• Light: protect from direct sunlight (amber glass or opaque container)
• Humidity: keep dry (moisture degrades polysaccharides)
• Shelf life: 2-3 years unopened; 12-18 months opened
• No special refrigeration required

Palatability & Compliance

• Taste: Mild, earthy, umami (fruiting body); milder (mycelium); slightly bitter (concentrated extracts)
• Best mixing: Coffee/tea (traditional "mushroom coffee"); smoothies; soups/broths
• Capsules: Most convenient, no taste, highest compliance
• Compliance tip: Morning with breakfast is the simplest habit stack. One dose daily beats three divided doses for adherence.

Exercise & Circadian Timing

• Morning (preferred): Aligns with peak cortisol and cognitive performance window; supports daytime neuroplasticity
• Evening (acceptable): Supports neurogenesis during sleep; may promote sleep quality via anxiolytic effects (no stimulant properties)
• Post-workout: May support exercise-induced BDNF enhancement (theoretical)
• Cycling: NOT necessary. Continuous daily use is standard and supported by clinical trials. No tolerance development observed. Benefits reverse within 4 weeks of cessation (Mori 2009).

Reference Ranges (Expected Biomarker Changes)

No established therapeutic blood levels for Lion's Mane compounds. Cognitive testing (MMSE, MoCA) is the gold standard for tracking benefit, not blood biomarkers.

Cost

Best value for cognitive enhancement: fruiting body extract ($30-45/month with strong RCT evidence). Premium option: EAHE (justified for MCI or early AD based on Li 2020).

What We Don't Know

• Optimal dose for each indication (no dose-response curves in humans)
• Whether fruiting body or mycelium is clinically superior (no head-to-head RCT)
• Long-term safety beyond 49 weeks
• Human pharmacokinetics (absorption, distribution, metabolism, excretion)
• Effects in children and adolescents (one pilot only)
• Safety in pregnancy and lactation
• Whether the r/LionsManeRecovery neuropsychiatric reports reflect a real subpopulation effect or confounders
• Whether the libido concern has any basis in H. erinaceus specifically
• Pharmacogenomic modifiers (zero studies)
• Efficacy in moderate-to-severe dementia (only MCI and early AD studied)
• Whether product quality variation accounts for most of the works/doesn't-work divide
• Optimal duration of treatment and whether intermittent dosing preserves benefits
• Whether cognitive benefits in healthy young adults are clinically meaningful or just statistically significant
• How gut microbiome changes from Lion's Mane mediate brain effects (gut-brain axis mechanism)

References

Systematic Reviews

1. Menon A et al. (2025). Benefits, side effects, and uses of HE as a supplement: systematic review. Front Nutr 12:1641246. PMID: 40959699. — 5 RCTs, 15 lab studies, 3 pilot trials reviewed.
2. Spangenberg ET et al. (2025). Erinacines in neuroprotective effects: systematic review of preclinical models. Front Pharmacol. PMID: 40626304.
3. Taib NAB et al. (2026). Medicinal mushrooms for peripheral nerve injury: systematic review. Med Sci. PMID: 41562932.
4. Shu M et al. (2025). Fungal supplementation on endurance, immune, hematological profiles in athletes: systematic review + meta-analysis. Front Nutr. PMID: 41280379.

Landmark RCTs (Human)

5. Mori K et al. (2009). Improving effects of Yamabushitake on MCI: double-blind placebo-controlled trial. Phytother Res 23(3):367-72. PMID: 18844328. — 3000 mg/day, 16 weeks, N=30, significant cognitive improvement.
6. Saitsu Y et al. (2019). Improvement of cognitive functions by oral intake of HE. Biomed Res 40(4):125-131. PMID: 31413233. — 1960 mg/day, 12 weeks, N=31, improved cognition in healthy elderly.
7. Nagano M et al. (2010). Reduction of depression and anxiety by 4 weeks HE intake. Biomed Res 31(4):231-7. PMID: 20834180. — N=30 menopausal women, significant mood improvement.
8. Li IC et al. (2020). Prevention of Early AD by EAHE Pilot RCT. Front Aging Neurosci 12:155. PMID: 32581767. — 1050 mg/day EAHE, 49 weeks, N=49, MMSE stability.
9. Vigna L et al. (2019). HE Improves Mood and Sleep in Overweight/Obesity. Evid Based Complement Alternat Med 2019:7861297. PMID: 31118969. — Improved depression, anxiety, sleep; increased BDNF.
10. Docherty S et al. (2023). Acute and chronic effects of Lion's Mane on cognition, stress, mood. RCT. J Funct Foods. PMID: 38004235. — 1.8 g/day, 28 days, N=41 young adults, improved stress/mood/speed.
11. Surendran G et al. (2025). Acute cognitive and mood improvements from standardized HE extract. Front Nutr. PMID: 40276537. — Single-dose acute effects in young adults.
12. La Monica MB et al. (2023). Acute cognitive performance from Lion's Mane vs Guayusa. RCT crossover. PMID: 38140277. — N=40, single-dose.
13. Chan YC et al. (2022). EAHE in elderly hearing impairment. J Funct Foods 97:105220. — 2000 mg/day EAHE, 8 months, N=80, improved high-frequency hearing + BDNF.
14. Li IC et al. (2024). Erinacine A, cognition, and gut microbiome pilot. J Funct Foods 115:106120. — 8 weeks, N=33, improved cognition, microbiome diversity correlated with NPY.
15. Xu CP et al. (1985). Double-blind RCT for chronic atrophic gastritis. PMID: 3932005. — Earliest clinical trial.
16. Tursi A et al. (2025). HE-based nutraceutical for post-colonoscopy syndrome. Nutrients. PMID: 41097229. — Retrospective multicentre.
17. Dimitrov MA et al. (2026). HE biomass supplement in children with intellectual disabilities. Nutrients. PMID: 41599861. — Novel pediatric population.
18. Bertani B et al. (2026). Multi-compound supplement in symptomatic uncomplicated diverticular disease. Minerva Gastroenterol. PMID: 41910467.

Mechanism Studies

19. Mori K et al. (2008). NGF-inducing activity in human astrocytoma cells. Biol Pharm Bull 31(9):1727-32. PMID: 18758067. — Hericenones C-E stimulate NGF.
20. Huang HT et al. (2021). Mycelium promotes oligodendrocyte maturation + MBP. Sci Rep 11(1):6551. PMID: 33753806.
21. Martinez-Marmol R et al. (2023). Hericerin derivatives activate pan-neurotrophic ERK1/2 pathway. J Neurochem 165(6):791-808. PMID: 36660878.
22. Ryu S et al. (2018). HE extract reduces anxiety/depression by promoting hippocampal neurogenesis. J Med Food 21(2):174-180. PMID: 29091526.
23. Brandalise F et al. (2025). HE extracts promote neuronal differentiation and excitability. Biomed Pharmacother. PMID: 40413998.
24. Cipriano C et al. (2026). Neurotrophic-epigenetic axis via non-coding RNA networks. Int J Mol Sci. PMID: 41683696.
25. Bui TT et al. (2024). Erinacines on microglial regulation in AD under metabolic stress. CNS Neurosci Ther. PMID: 39690860.
26. Lee LY et al. (2024). Novel erinacines cerebral protection in mild TBI via Nrf2. Antioxidants. PMID: 38539904.
27. Wang G et al. (2024). Amyloban ameliorates social deficits, suppresses dopaminergic enhancement. Neuropsychopharmacol Rep. PMID: 39263933.
28. Ha TM et al. (2025). Anti-inflammatory via JAK1/STAT3 in macrophages. BMB Rep. PMID: 41168894.
29. Hernandez-Munguia S et al. (2026). Molecular dynamics: erinacines binding to iNOS and NF-kB. Int J Mol Sci. PMID: 41977330.
30. Tabecka-Lonczynska A et al. (2025). HE metabolites activate AhR in neuronal HT-22 cells. Pharmacol Rep. PMID: 40810764.
31. Mahema G et al. (2026). Bioactives targeting PPAR signaling pathway. Int J Med Mushrooms. PMID: 41915570.
32. Cao L et al. (2025). New neuroprotective terpenoids from fruiting bodies. Int J Mol Sci. PMID: 40724855.
33. Lin CW et al. (2024). Discovery of erinacerin W — immunomodulatory + neuroprotective. Molecules. PMID: 38398564.
34. Li X et al. (2024). Hericenone C attenuates nociceptive behavior. Biochem Biophys Res Commun. PMID: 38759303.

Cross-Domain Studies

35. Chen YH et al. (2026). HE + Cordyceps cicadae promote retinal ganglion cell neurite outgrowth. PLoS One. PMID: 41650116.
36. Lee LY et al. (2026). EAHE + undenatured type II collagen reduces osteoarthritis. Int J Med Sci. PMID: 41799751.
37. Hwang CF et al. (2025). Mycelium improves male reproductive dysfunction from microplastics. Int J Mol Sci. PMID: 40565199.
38. Wu CC et al. (2024). Erinacine A in SCA3 via Nrf2 activation. Antioxidants. PMID: 39765823.
39. Radanovic M et al. (2026). Triple neuromodulatory axis: HE + lithium + B12 for nerve regeneration. Int J Clin Pharmacol Ther. PMID: 41878942.
40. Baker J, Newman A (2025). Theoretical potential as add-on to antipsychotics in schizophrenia. Psychopharmacol Bull. PMID: 39935672.
41. ALSUntangled #73 (2024). Expert panel assessment for ALS. PMID: 38141002.

GI / Microbiome Studies

42. Yu X et al. (2026). Beta-glucan extract ameliorates acute colitis. Int J Biol Macromol. PMID: 41819322.
43. Li Y et al. (2024). Polysaccharides alleviate UC via NLRP3 inflammasome inhibition. Int J Biol Macromol. PMID: 38556226.
44. Liu R et al. (2025). Low-MW beta-glucan restores mitochondrial function in alcohol-induced GI injury. J Agric Food Chem. PMID: 41159373.
45. Pellegrino R, Gravina A (2025). HE in chronic atrophic gastritis — TCM perspective. World J Gastroenterol. PMID: 40495939.
46. Song Y et al. (2025). Comprehensive review: polysaccharides and GI effects. Int J Biol Macromol. PMID: 40339863.

Metabolic Studies

47. Yang J et al. (2025). Hypoglycemic effect of HE buccal tablets in diabetic mice. Biology. PMID: 41300379.
48. Wang Q et al. (2025). Insoluble dietary fiber + puerarin alleviates HFD-induced obesity. Appl Environ Microbiol. PMID: 39976439.
49. Lu J et al. (2025). HE protein alleviates hepatic lipid accumulation. Foods. PMID: 39942052.
50. Wu X et al. (2026). Ultrasonic-degraded beta-glucan enhances hypolipidemic activities. Int J Biol Macromol. PMID: 41780782.

Cancer Studies (Preclinical)

51. Hou XX et al. (2020). Polysaccharides induce apoptosis in CRC cells via ROS/caspase-9. Food Funct 11(7):6128-6138. PMID: 32573644.
52. Tung SY et al. (2025). Erinacine S derivative overcomes chemoresistance in CRC via histone acetylation. Int J Med Sci. PMID: 41209562.
53. Atmaca M et al. (2024). HE induces apoptosis in prostate cancer via PI3K/AKT + RAS/MAPK. Chem Biodivers. PMID: 39183463.
54. Mai Huong T et al. (2024). Hericium VN — novel cytotoxic compound against brain astrocytoma. J Asian Nat Prod Res. PMID: 38572975.

Safety & Toxicology

55. Li IC et al. (2014). 28-day oral toxicity of EAHE in rats: no adverse effects at 5000 mg/kg. Food Chem Toxicol 70:61-7. PMID: 24810469.
56. Chen SN et al. (2022). Subchronic toxicity and genotoxicity of HE beta-glucan: negative. Curr Res Toxicol 3:100068. PMID: 35341120.
57. Lakshmanan H et al. (2016). Sub-chronic toxicological assessment in rodents: no adverse effects. J Ethnopharmacol 194:1051-1059. PMID: 27816657.
58. Mahadevan B et al. (2025). Formal toxicological assessment of HE and Trametes versicolor powders. Front Toxicol. PMID: 41230556.
59. Strobbe G et al. (2025). Grade 3 cytolysis case report in metastatic CRC patient. J Oncol Pharm Pract. PMID: 39223928.

Reviews

60. Friedman M (2015). Chemistry, Nutrition, Health-Promoting Properties of HE. J Agric Food Chem 63(32):7108-23. PMID: 26244378.
61. Szucko-Kociuba I et al. (2023). Neurotrophic and Neuroprotective Effects of HE. Int J Mol Sci 24(21):15960. PMID: 37958943.
62. Cornford A, Charnley D (2025). HE: possible future treatment for AD? Narrative review. Nutr Res Rev. PMID: 39988819.
63. Amen S et al. (2026). Chemistry and bioactivities of erinacines. J Nat Med. PMID: 41801298.
64. Othman N et al. (2026). Hericenones scoping review: structural diversity and health benefits. Chem Biodivers. PMID: 41518660.
65. Emil A et al. (2025). Dietary HE affects stress coping, depressive/anxiety behavior. J Pharm Pharmacol. PMID: 40974039.
66. Romano R et al. (2024). Therapeutic role in urogenital-gut axis. J Physiol Pharmacol. PMID: 38583434.

Pharmacokinetics

67. Hu JH et al. (2019). Absolute bioavailability, tissue distribution of erinacine S. Molecules 24(8):1624. PMID: 31022946.
68. Tsai PC et al. (2021). Preclinical bioavailability of erinacine A — validated LC-MS/MS. Molecules 26(15):4510. PMID: 34361662.

Mood / Psychiatric

69. Fu SP et al. (2024). Erinacine S protects oligodendrocytes, alleviates mood abnormalities. Biomed Pharmacother. PMID: 38394854.
70. Gong Y et al. (2025). Edible/medicinal fungi as natural antidepressants — review. Mol Nutr Food Res. PMID: 40289452.
71. Karcioglu Batur L et al. (2025). Kiperin Mind Focus mitigates chronic stress-induced neuroinflammation. Front Integr Neurosci. PMID: 41695889.